Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  OpGen  /  Curetis 2018

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel OpGen OTC:OPGN.Q, US68373L4068

  • 0,600 17 apr 2024 21:59
  • 0,000 (0,00%) Dagrange 0,000 - 0,000
  • 119 Gem. (3M) 1,7M

Curetis 2018

2.047 Posts
Pagina: «« 1 ... 78 79 80 81 82 ... 103 »» | Laatste | Omlaag ↓
  5. MegaTelstar 7 augustus 2018 14:17
    Volgens mij zijn de trossen al enkele uren geleden losgegooid. Ik ga pas winnen als de koers € 5,70 is gepasseerd, maar goed mijn verlies wordt rap minder... Ik zie een tweede freeze vanmiddag nog wel langskomen en dat met dit weer. It will overboil lijkt mij een betere term voor vandaag.
    groet, SuperTelstar
  8. Noob nr1 7 augustus 2018 14:24
    quote:

    joanwillem schreef op 7 augustus 2018 14:07:

    [...]

    Lucas even kijken op Finanzen.net , daar staan meerdere persberichten
    op van Curetis.

    joanb

    Bedankt voor de info, zag het zelf op Binck. Weliswaar weer niet bij het algemene nieuws te lezen wel als je naar het aandeel zelf gaat.
    Hopelijk terug naar hogere koersstanden toen er overname speculatie inzat
  10. nightrider 7 augustus 2018 14:29
    quote:

    MegaTelstar schreef op 7 augustus 2018 14:17:

    Volgens mij zijn de trossen al enkele uren geleden losgegooid. Ik ga pas winnen als de koers € 5,70 is gepasseerd, maar goed mijn verlies wordt rap minder... Ik zie een tweede freeze vanmiddag nog wel langskomen en dat met dit weer. It will overboil lijkt mij een betere term voor vandaag.
    groet, SuperTelstar
    Let's hope for U
  13. forum rang 8 lucas D 7 augustus 2018 16:08
    quote:

    BLUE001 schreef op 7 augustus 2018 15:02:

    read:https://www.trivano.com/aandeel/curetis-expands-geographic-presence.18913-70817.persbericht
    Curetis Expands Geographic Presence with Entry into Northern African and Latin American Markets

    www.trivano.com

    Curetis Expands Geographic Presence with Entry into Northern African and Latin American Markets
    New Unyvero distribution partnerships in Egypt, Mexico, and Uruguay
    Contractual commitments for 45 Unyvero Systems

    Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, August 07, 2018 , 09:30 a.m. EDT - Curetis N.V. (the " Company " and together with its subsidiaries " Curetis "), a developer of next-level molecular diagnostic solutions, today announced exclusive distribution partnerships in Egypt, Mexico, and Uruguay with Future Horizon Scientific, Quimica Valaner S.A. de C.V., and Biko S.A., respectively. The signing of these agreements follows a systematic qualification process conducted by Curetis, which focused on identifying distributors that are experienced in commercializing innovative products for international molecular diagnostics companies.
    Each of the three new distribution partners intends to commercialize all five Unyvero Application Cartridges that are currently CE-IVD-marked: HPN for pneumonia, ITI for implant and tissue infections, BCU for bloodstream infections, IAI for intra-abdominal infections, and UTI for urinary tract infections. To establish the installed base of Unyvero Analyzers required to run these cartridge-based tests, the partners have in total committed to purchasing a minimum of 45 Unyvero systems at Curetis' distributor transfer prices over a three-year period. In addition, they have collectively committed to minimum purchases of several thousand Application Cartridges over the term of the agreements.
    The agreements will allow Curetis to expand its commercial reach into countries in Northern Africa and Latin America. Initial commercialization activities are expected to begin in the fourth quarter of 2018, following product registrations in the respective countries. The process of registering Unyvero in each of these countries has been initiated following the execution of the respective agreements.

    "We are excited to partner with Future Horizon Scientific, Quimica Valaner, and Biko as top-tier distributors that have built strong track records in working with companies like QIAGEN, Bio-Rad, Bruker, and GE Healthcare," said Oliver Schacht, PhD, Chief Executive Officer of Curetis. "Egypt, Mexico, and Uruguay are important countries in the Northern African and Latin American healthcare markets. We anticipate that selling our products through partners in these markets will increasingly contribute to our revenue growth in the coming years. Within just a few months of joining the Company, our new Head of Global Commercial Partner Management, Eneko Goya, has not only negotiated and closed these three agreements, but has also generated a strong pipeline and a very healthy funnel of new distribution partnership opportunities, which we intend to drive to contract closures in the coming months."

    "Since its foundation, Quimica Valaner's spirit has been the introduction of reliable and innovative diagnostic technologies to the Mexican market", said Homero Hernandez, CEO of Quimica Valaner. "We are convinced that Curetis' Unyvero solution will resolve important limitations in the diagnosis of infectious diseases in Mexico, creating a direct benefit for the quality-of-life of the Mexican population as well as a sustainable and successful business alliance between Quimica Valaner and Curetis."
    To-date, Curetis has signed 16 distribution partnerships covering 29 countries and is planning to expand its distribution network and commercial reach through further partnerships with suitably positioned distributors.
    ###
    About Curetis
    Curetis N.V.'s (Euronext: CURE) goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.
    Curetis' Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures, thereby facilitating improved patient outcomes, stringent antibiotic stewardship and health-economic benefits. Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.

    Curetis' wholly owned subsidiary Ares Genetics GmbH offers next-generation solutions for infectious disease diagnostics and therapeutics. The ARES Technology Platform combines what the Company believes to be the most comprehensive database worldwide on the genetics of antimicrobial resistances, ARES db , with advanced bioinformatics and artificial intelligence.
    For further information, please visit www.curetis.com and www.ares-genetics.com .
    Legal Disclaimer
    This document constitutes neither an offer to buy nor an offer to subscribe for securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
    The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
    This press release includes statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "targets," "may," "will," or "should" and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis' actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
    Contact details
    Curetis' Contact Details
    Curetis GmbH
    Max-Eyth-Str. 42
    71088 Holzgerlingen, Germany
    Tel. +49 7031 49195-10
    pr@curetis.com or ir@curetis.com
    www.curetis.com - www.unyvero.com
    International Media & Investor Inquiries
    akampion
    Dr. Ludger Wess / Ines-Regina Buth
    Managing Partners
    info(@)akampion.com
    Tel. +49 40 88 16 59 64
    Tel. +49 30 23 63 27 68
    U.S. Media & Investor Inquiries
    The Ruth Group
    Lee Roth
    lroth@theruthgroup.com
    Tel. +1 646 536 7012
2.047 Posts
Pagina: «« 1 ... 78 79 80 81 82 ... 103 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!